Jeonghyun Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jeonghyun Choi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Yonggeun Hong
Department of Digital Anti-Aging Healthcare, Graduate School of Inje University, Gimhae 50834, Republic of Korea
19 shared publications - Dewan Md. Sumsuzzman
Agent-Based Modelling Laboratory, York University, Toronto, ON M3J 1P3, Canada
9 shared publications - Yunho Jin
Department of Rehabilitation Science, Graduate School of Inje University, Gimhae 50834, Korea
8 shared publications - Zeeshan Ahmad Khan
Department of Anesthesiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
6 shared publications - Sang-Rae Lee
Efficacy Test Center for Mental & Behavioral Disorders, Ajou University Hospital, Suwon 16499, Republic of Korea
4 shared publications Seunghoon Lee
Biohealth Products Research Center (BPRC), Inje University, Gimhae, South Korea; Research Center for Aged-life Redesign (RCAR), Inje University, Gimhae, South Korea; Department of Physical Therapy, College of Healthcare Medical Science & Engineering, Inje University, Gimhae, South Korea
3 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1885078
Translational rehabilitation strategies for canine medial patellar luxation: insights from human patellofemoral pain syndrome
Medial patellar luxation (MPL) is one of the most common orthopedic disorders in small-breed dogs and is associated with progressive joint degeneration, gait abnormalities, and long-term functional impairment. Despite its high prevalence, current treatment strategies remain primarily focused on structural correction, whereas rehabilitation approaches targeting dynamic patellar stability and functional recovery remain insufficiently established. In particular, rehabilitation concepts addressing muscle function, multi-joint coordination, and neuromuscular regulation have not been systematically integrated into current veterinary rehabilitation paradigms. In human medicine, patellofemoral pain syndrome (PFPS) has been extensively investigated as a disorder characterized by abnormal patellar tracking and dynamic patellar instability associated with altered muscle function and impaired neuromuscular control. Based on these pathophysiological and rehabilitation concepts, this review examined the translational relevance of PFPS-derived rehabilitation strategies to canine MPL. Comparative analysis suggested the presence of partially shared biomechanical characteristics related to patellar tracking and quadriceps function between humans and dogs, despite substantial interspecies differences in gait mechanics and limb loading. Evidence from PFPS rehabilitation studies suggests that interventions emphasizing coordinated muscle function, multi-joint coordination, neuromuscular control, and gait retraining may contribute to restoration of dynamic patellar stability. Accordingly, this review proposes a phase-based, species-adapted translational rehabilitation framework for canine MPL consisting of muscle activation, restoration of multi-joint coordination, neuromuscular regulation, and gait retraining. Although current biomechanical and clinical evidence in dogs remains limited, this framework may provide a conceptual foundation for future function-oriented rehabilitation strategies and prospective validation studies, thereby supporting expansion of canine MPL management beyond structural correction alone toward long-term functional recovery and recurrence prevention.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1885078
Open AccessTranslational rehabilitation strategies for canine medial patellar luxation: insights from human patellofemoral pain syndrome
Medial patellar luxation (MPL) is one of the most common orthopedic disorders in small-breed dogs and is associated with progressive joint degeneration, gait abnormalities, and long-term functional impairment. Despite its high prevalence, current treatment strategies remain primarily focused on structural correction, whereas rehabilitation approaches targeting dynamic patellar stability and functional recovery remain insufficiently established. In particular, rehabilitation concepts addressing muscle function, multi-joint coordination, and neuromuscular regulation have not been systematically integrated into current veterinary rehabilitation paradigms. In human medicine, patellofemoral pain syndrome (PFPS) has been extensively investigated as a disorder characterized by abnormal patellar tracking and dynamic patellar instability associated with altered muscle function and impaired neuromuscular control. Based on these pathophysiological and rehabilitation concepts, this review examined the translational relevance of PFPS-derived rehabilitation strategies to canine MPL. Comparative analysis suggested the presence of partially shared biomechanical characteristics related to patellar tracking and quadriceps function between humans and dogs, despite substantial interspecies differences in gait mechanics and limb loading. Evidence from PFPS rehabilitation studies suggests that interventions emphasizing coordinated muscle function, multi-joint coordination, neuromuscular control, and gait retraining may contribute to restoration of dynamic patellar stability. Accordingly, this review proposes a phase-based, species-adapted translational rehabilitation framework for canine MPL consisting of muscle activation, restoration of multi-joint coordination, neuromuscular regulation, and gait retraining. Although current biomechanical and clinical evidence in dogs remains limited, this framework may provide a conceptual foundation for future function-oriented rehabilitation strategies and prospective validation studies, thereby supporting expansion of canine MPL management beyond structural correction alone toward long-term functional recovery and recurrence prevention.
- Open Access
Gut-Derived Metabolic Imbalance in Autism Spectrum Disorder: Toward the Concept of a Metabolic Subtype
Autism spectrum disorder (ASD) is highly heterogeneous in symptom onset and severity, comorbidities, and treatment responsiveness, challenging the notion of a single pathogenic mechanism. Increasing evidence indicates that some individuals with ASD exhibit prominent peripheral physiological alterations, including gastrointestinal (GI) dysfunction, gut microbial dysbiosis, immune imbalance, oxidative stress, and mitochondrial/energy metabolic vulnerability. In this context, gut-derived metabolites—particularly short-chain fatty acids (SCFAs)—have emerged as plausible modulators of the neurodevelopmental milieu through the expanded gut–immune–metabolic–brain axis. This review synthesizes: (i) SCFAs’ biogenesis and physiological roles, (ii) context- and developmental stage-dependent effects, (iii) the clinical heterogeneity of reported microbiome and SCFA alterations in ASD, and (iv) propionate as a frequently discussed candidate signal and the interpretive boundaries of preclinical evidence. Human studies show substantial inter-study variability in SCFA alterations (increases, decreases, or no differences), influenced by factors such as sample type (stool vs. blood), GI symptoms, diet, medication exposure, and analytical variability. Accordingly, SCFAs should not be treated as universal ASD biomarkers but rather as context-dependent metabolic signals relevant under specific clinical and biological conditions. Building on this premise, we propose the conceptual framework of “metabolic ASD” representing a metabolically informed dimension of biological variability in which peripheral metabolic–immune perturbations may contribute to neurodevelopmental vulnerability. To avoid premature causal claims, we outline design requirements for future research, including stratified study designs, longitudinal cohorts, and integrative multi-layer analyses. Ultimately, metabolic ASD should be positioned as a testable precision medicine research framework rather than a universal etiological model.
Open AccessGut-Derived Metabolic Imbalance in Autism Spectrum Disorder: Toward the Concept of a Metabolic Subtype
Autism spectrum disorder (ASD) is highly heterogeneous in symptom onset and severity, comorbidities, and treatment responsiveness, challenging the notion of a single pathogenic mechanism. Increasing evidence indicates that some individuals with ASD exhibit prominent peripheral physiological alterations, including gastrointestinal (GI) dysfunction, gut microbial dysbiosis, immune imbalance, oxidative stress, and mitochondrial/energy metabolic vulnerability. In this context, gut-derived metabolites—particularly short-chain fatty acids (SCFAs)—have emerged as plausible modulators of the neurodevelopmental milieu through the expanded gut–immune–metabolic–brain axis. This review synthesizes: (i) SCFAs’ biogenesis and physiological roles, (ii) context- and developmental stage-dependent effects, (iii) the clinical heterogeneity of reported microbiome and SCFA alterations in ASD, and (iv) propionate as a frequently discussed candidate signal and the interpretive boundaries of preclinical evidence. Human studies show substantial inter-study variability in SCFA alterations (increases, decreases, or no differences), influenced by factors such as sample type (stool vs. blood), GI symptoms, diet, medication exposure, and analytical variability. Accordingly, SCFAs should not be treated as universal ASD biomarkers but rather as context-dependent metabolic signals relevant under specific clinical and biological conditions. Building on this premise, we propose the conceptual framework of “metabolic ASD” representing a metabolically informed dimension of biological variability in which peripheral metabolic–immune perturbations may contribute to neurodevelopmental vulnerability. To avoid premature causal claims, we outline design requirements for future research, including stratified study designs, longitudinal cohorts, and integrative multi-layer analyses. Ultimately, metabolic ASD should be positioned as a testable precision medicine research framework rather than a universal etiological model.
- Open Access
- 15 April 2026
- Published by MDPI AG in Preprints.org
Gut-Derived Metabolic Imbalance in Autism Spectrum Disorder: Toward the Concept of a Metabolic Subtype
Autism spectrum disorder (ASD) is highly heterogeneous in symptom onset and severity, comorbidities, and treatment responsiveness, challenging a single “brain-centered” pathogenic model. Increasing evidence indicates that a subset of individuals with ASD exhibits prominent peripheral physiological alterations, including gastrointestinal (GI) dysfunction, gut microbial dysbiosis, immune imbalance, oxidative stress, and mito-chondrial/energy metabolic vulnerability. In this context, gut-derived metabo-lites—particularly short-chain fatty acids (SCFAs)—have emerged as plausible modula-tors of the neurodevelopmental milieu through the expanded gut–immune–metabolic–brain axis. This review synthesizes: (i) SCFA biogenesis and core physiological functions (GPCR-mediated signaling and epigenetic regulation), (ii) context- and developmental stage–dependent bidirectional effects shaped by dose, exposure duration, and tissue spec-ificity, (iii) the clinical heterogeneity of reported microbiome and SCFA alterations in ASD, and (iv) propionate as a frequently discussed candidate signal and the interpretive boundaries of preclinical evidence. Human studies show inconsistent directions and magnitudes of SCFA changes (increases, decreases, or no differences), driven by major sources of variability such as sample type (stool vs. blood, reflecting distinct physiological layers), GI symptom stratification, diet and medication/antibiotic exposure, and non-standardized analytical pipelines and reporting units. Accordingly, SCFAs should not be treated as universal ASD biomarkers; rather, they are better interpreted as con-text-dependent signals that may become salient under specific clinical-biological condi-tions. Building on this premise, we propose the conceptual framework of “metabolic ASD,” defined as a subtype in which peripheral metabolic–immune perturbations plausibly contribute to neurodevelopmental vulnerability. To avoid premature causal claims, we outline design requirements for future research, including developmentally informed lon-gitudinal cohorts, rigorous phenotypic stratification, standardized metabolomics, and multi-layer endpoints integrating barrier integrity, systemic inflammation, and metabolic stress. Ultimately, metabolic ASD should be positioned as a testable precision-medicine research frame rather than a universal etiological model.
- 15 April 2026
- Published by MDPI AG in Preprints.org
Open AccessGut-Derived Metabolic Imbalance in Autism Spectrum Disorder: Toward the Concept of a Metabolic Subtype
Autism spectrum disorder (ASD) is highly heterogeneous in symptom onset and severity, comorbidities, and treatment responsiveness, challenging a single “brain-centered” pathogenic model. Increasing evidence indicates that a subset of individuals with ASD exhibits prominent peripheral physiological alterations, including gastrointestinal (GI) dysfunction, gut microbial dysbiosis, immune imbalance, oxidative stress, and mito-chondrial/energy metabolic vulnerability. In this context, gut-derived metabo-lites—particularly short-chain fatty acids (SCFAs)—have emerged as plausible modula-tors of the neurodevelopmental milieu through the expanded gut–immune–metabolic–brain axis. This review synthesizes: (i) SCFA biogenesis and core physiological functions (GPCR-mediated signaling and epigenetic regulation), (ii) context- and developmental stage–dependent bidirectional effects shaped by dose, exposure duration, and tissue spec-ificity, (iii) the clinical heterogeneity of reported microbiome and SCFA alterations in ASD, and (iv) propionate as a frequently discussed candidate signal and the interpretive boundaries of preclinical evidence. Human studies show inconsistent directions and magnitudes of SCFA changes (increases, decreases, or no differences), driven by major sources of variability such as sample type (stool vs. blood, reflecting distinct physiological layers), GI symptom stratification, diet and medication/antibiotic exposure, and non-standardized analytical pipelines and reporting units. Accordingly, SCFAs should not be treated as universal ASD biomarkers; rather, they are better interpreted as con-text-dependent signals that may become salient under specific clinical-biological condi-tions. Building on this premise, we propose the conceptual framework of “metabolic ASD,” defined as a subtype in which peripheral metabolic–immune perturbations plausibly contribute to neurodevelopmental vulnerability. To avoid premature causal claims, we outline design requirements for future research, including developmentally informed lon-gitudinal cohorts, rigorous phenotypic stratification, standardized metabolomics, and multi-layer endpoints integrating barrier integrity, systemic inflammation, and metabolic stress. Ultimately, metabolic ASD should be positioned as a testable precision-medicine research frame rather than a universal etiological model.
- Open Access
Comparison of Wound Healing Effects of Different Micro-Patterned Hydrogels on the Skin of Secondary Intention Rat Model
Background: The skin acts as a barrier against external threats, and moisture is crucial for effective wound healing, as it promotes epithelial cell migration. Thus, a high water content supports wound healing by maintaining moisture, absorbing exudate, and forming a protective barrier. Here, we created three different micro-patterned hydrogels and tested them on rat skin wounds. Materials and Methods: Three different micro-patterned (waves, lines, and checks) hydrogel patches were created using three-dimensional polymer networks. On SD rat skin, wounds were created by making incisions, and the hydrogel patches were applied. The rats were divided into three experimental groups based on the hydrogel micro-patterns. Rats without hydrogel (vehicle) and those with flat hydrogel (no shape) were considered as controls. The wound closure rate (WCR) was calculated, and the expression of Col1A protein was measured by western blot. Results: After 7 days, the WCR was significantly higher in the groups treated with micro-patterned hydrogel patches compared to the vehicle and no-shape groups. Specifically, the WCR was highest in the checks micro-patterned hydrogel group compared to the waves and lines micro-patterned hydrogel groups. Furthermore, Col1A protein expression was evaluated at days 7 and 14, revealing a significant increase in expression after 14 days in the checks micro-patterned hydrogel group compared to the waves and lines micro-patterned hydrogel groups. Conclusions: The checks micro-patterned hydrogel patches demonstrated superior wound healing efficacy, as indicated by a higher WCR and increased Col1A protein expression after 14 days. These findings highlight the importance of hydrogel pattern design in improving wound healing suggesting that optimized micro-patterns can enhance therapeutic outcomes in skin wound management.
Open AccessComparison of Wound Healing Effects of Different Micro-Patterned Hydrogels on the Skin of Secondary Intention Rat Model
Background: The skin acts as a barrier against external threats, and moisture is crucial for effective wound healing, as it promotes epithelial cell migration. Thus, a high water content supports wound healing by maintaining moisture, absorbing exudate, and forming a protective barrier. Here, we created three different micro-patterned hydrogels and tested them on rat skin wounds. Materials and Methods: Three different micro-patterned (waves, lines, and checks) hydrogel patches were created using three-dimensional polymer networks. On SD rat skin, wounds were created by making incisions, and the hydrogel patches were applied. The rats were divided into three experimental groups based on the hydrogel micro-patterns. Rats without hydrogel (vehicle) and those with flat hydrogel (no shape) were considered as controls. The wound closure rate (WCR) was calculated, and the expression of Col1A protein was measured by western blot. Results: After 7 days, the WCR was significantly higher in the groups treated with micro-patterned hydrogel patches compared to the vehicle and no-shape groups. Specifically, the WCR was highest in the checks micro-patterned hydrogel group compared to the waves and lines micro-patterned hydrogel groups. Furthermore, Col1A protein expression was evaluated at days 7 and 14, revealing a significant increase in expression after 14 days in the checks micro-patterned hydrogel group compared to the waves and lines micro-patterned hydrogel groups. Conclusions: The checks micro-patterned hydrogel patches demonstrated superior wound healing efficacy, as indicated by a higher WCR and increased Col1A protein expression after 14 days. These findings highlight the importance of hydrogel pattern design in improving wound healing suggesting that optimized micro-patterns can enhance therapeutic outcomes in skin wound management.
- 22 September 2023
- Published by Elsevier in Brain Research
- Vol. 1820, 148588
Suppression of DAPK1 reduces ischemic brain injury through inhibiting cell death signaling and promoting neural remodeling
- 22 September 2023
- Published by Elsevier in Brain Research
- Vol. 1820, 148588
Suppression of DAPK1 reduces ischemic brain injury through inhibiting cell death signaling and promoting neural remodeling
- 7 September 2022
- Published by Elsevier in Ageing Research Reviews
- Vol. 81, 101729
Assessment of functional roles and therapeutic potential of integrin receptors in osteoarthritis: A systematic review and meta-analysis of preclinical studies
- 7 September 2022
- Published by Elsevier in Ageing Research Reviews
- Vol. 81, 101729
Assessment of functional roles and therapeutic potential of integrin receptors in osteoarthritis: A systematic review and meta-analysis of preclinical studies
- Open Access
- 5 May 2022
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 28 (8) , 1168-1182
Pre‐ and post‐conditioning with poly I:C exerts neuroprotective effect against cerebral ischemia injury in animal models: A systematic review and meta‐analysis
Background Toll-like receptor (TLR) agonist polyinosinic-polycytidylic acid (poly I:C) exerts neuroprotective effects against cerebral ischemia (CI), but concrete evidence supporting its exact mechanism of action is unclear. Methods We evaluated the neuroprotective role of poly I:C by assessing CI indicators such as brain infarct volume (BIV), neurological deficit score (N.S.), and signaling pathway proteins. Moreover, we performed a narrative review to illustrate the mechanism of action of TLRs and their role in CI. Our search identified 164 articles and 10 met the inclusion criterion. Results Poly I:C reduces BIV and N.S. (p = 0.00 and p = 0.03). Interestingly, both pre- and post-conditioning decrease BIV (preC p = 0.04 and postC p = 0.00) and N.S. (preC p = 0.03 and postC p = 0.00). Furthermore, poly I:C upregulates TLR3 [SMD = 0.64; CIs (0.56, 0.72); p = 0.00], downregulates nuclear factor-kappa B (NF-kappa B) [SMD = -1.78; CIs (-2.67, -0.88); p = 0.0)], and tumor necrosis factor alpha (TNF-alpha) [SMD = -16.83; CIs (-22.63, -11.02); p = 0.00]. Conclusion We showed that poly I:C is neuroprotective and acts via the TLR3/NF-kappa B/TNF-alpha pathway. Our review indicated that suppressing TLR 2/4 may illicit neuroprotection against CI. Further research on simultaneous activation of TLR3 with poly I:C and suppression of TLR 2/4 might open new vistas for the development of therapeutics against CI.
- 5 May 2022
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 28 (8) , 1168-1182
Open AccessPre‐ and post‐conditioning with poly I:C exerts neuroprotective effect against cerebral ischemia injury in animal models: A systematic review and meta‐analysis
Background Toll-like receptor (TLR) agonist polyinosinic-polycytidylic acid (poly I:C) exerts neuroprotective effects against cerebral ischemia (CI), but concrete evidence supporting its exact mechanism of action is unclear. Methods We evaluated the neuroprotective role of poly I:C by assessing CI indicators such as brain infarct volume (BIV), neurological deficit score (N.S.), and signaling pathway proteins. Moreover, we performed a narrative review to illustrate the mechanism of action of TLRs and their role in CI. Our search identified 164 articles and 10 met the inclusion criterion. Results Poly I:C reduces BIV and N.S. (p = 0.00 and p = 0.03). Interestingly, both pre- and post-conditioning decrease BIV (preC p = 0.04 and postC p = 0.00) and N.S. (preC p = 0.03 and postC p = 0.00). Furthermore, poly I:C upregulates TLR3 [SMD = 0.64; CIs (0.56, 0.72); p = 0.00], downregulates nuclear factor-kappa B (NF-kappa B) [SMD = -1.78; CIs (-2.67, -0.88); p = 0.0)], and tumor necrosis factor alpha (TNF-alpha) [SMD = -16.83; CIs (-22.63, -11.02); p = 0.00]. Conclusion We showed that poly I:C is neuroprotective and acts via the TLR3/NF-kappa B/TNF-alpha pathway. Our review indicated that suppressing TLR 2/4 may illicit neuroprotection against CI. Further research on simultaneous activation of TLR3 with poly I:C and suppression of TLR 2/4 might open new vistas for the development of therapeutics against CI.
- Open Access
- 22 February 2022
- Published by Elsevier in Ageing Research Reviews
- Vol. 76, 101593
Neurodegenerative effect of DAPK1 after cerebral hypoxia-ischemia is associated with its post-transcriptional and signal transduction regulations: A systematic review and meta-analysis
- 22 February 2022
- Published by Elsevier in Ageing Research Reviews
- Vol. 76, 101593
Open AccessNeurodegenerative effect of DAPK1 after cerebral hypoxia-ischemia is associated with its post-transcriptional and signal transduction regulations: A systematic review and meta-analysis
- Open Access
- 17 September 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Melatonin Maintains Anabolic-Catabolic Equilibrium and Regulates Circadian Rhythm During Osteoarthritis Development in Animal Models: A Systematic Review and Meta-analysis
Background: The driving force behind osteoarthritis (OA) pathogenesis is an anabolic-catabolic (a/c) imbalance. Melatonin (MT) is a key player in maintaining a/c stability and mitigates OA pathogenesis, but mechanisms underlying its effects remain poorly understood.Objectives: We performed a systematic review analyzing the experimental data that support the clinical applicability of MT in the treatment of OA pathogenesis, placing particular emphasis on the regulation of circadian rhythms and a/c balance.Methods: Major electronic databases and grey literature were used to identify related original articles. Methodological quality of all selected studies was evaluated using the SYRCLE risk of bias tool. Pooled mean differences (MDs)/standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated to estimate the effect size.Results: Eleven trials were included in this systematic review. Compared with the control group, MT significantly decreased the levels of interleukin-1β (IL-1β; SMD = −5.45; 95% CI [−6.78, −4.12]; p < 0.00001, and histological grading scale (SMD = −3.46; 95% CI, [−5.24, −1.68]; p < 0.0001). MT significantly increased the transforming growth factor-β1 (TGF-β1; SMD = 1.17; 95% CI [0.31, 2.03]; p < 0.0007). Furthermore, core circadian clock genes Per2 and Cry1 mRNA levels were regulated by MT treatment in OA progression.Conclusion: MT may maintain a/c balance and regulate circadian rhythms during OA development. MT could be used in as adjunct with other interventions to manage pain and OA severity.
- 17 September 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessMelatonin Maintains Anabolic-Catabolic Equilibrium and Regulates Circadian Rhythm During Osteoarthritis Development in Animal Models: A Systematic Review and Meta-analysis
Background: The driving force behind osteoarthritis (OA) pathogenesis is an anabolic-catabolic (a/c) imbalance. Melatonin (MT) is a key player in maintaining a/c stability and mitigates OA pathogenesis, but mechanisms underlying its effects remain poorly understood.Objectives: We performed a systematic review analyzing the experimental data that support the clinical applicability of MT in the treatment of OA pathogenesis, placing particular emphasis on the regulation of circadian rhythms and a/c balance.Methods: Major electronic databases and grey literature were used to identify related original articles. Methodological quality of all selected studies was evaluated using the SYRCLE risk of bias tool. Pooled mean differences (MDs)/standardized mean differences (SMDs) with 95% confidence intervals (CIs) were calculated to estimate the effect size.Results: Eleven trials were included in this systematic review. Compared with the control group, MT significantly decreased the levels of interleukin-1β (IL-1β; SMD = −5.45; 95% CI [−6.78, −4.12]; p < 0.00001, and histological grading scale (SMD = −3.46; 95% CI, [−5.24, −1.68]; p < 0.0001). MT significantly increased the transforming growth factor-β1 (TGF-β1; SMD = 1.17; 95% CI [0.31, 2.03]; p < 0.0007). Furthermore, core circadian clock genes Per2 and Cry1 mRNA levels were regulated by MT treatment in OA progression.Conclusion: MT may maintain a/c balance and regulate circadian rhythms during OA development. MT could be used in as adjunct with other interventions to manage pain and OA severity.
- Open Access
- 1 August 2021
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 127, 459-473
Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials
- 1 August 2021
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 127, 459-473
Open AccessNeurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials